Answer
Yes, neutropenia and febrile neutropenia have been reported in patients receiving Elrexfio (elranatamab), and complete blood cell counts should be monitored at baseline and periodically during treatment.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked